**NOTICE OF PUBLIC MEETING – DRUG USE REVIEW BOARD**

<table>
<thead>
<tr>
<th>Date of Posting:</th>
<th>March 26, 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date of Meeting:</td>
<td>April 30, 2020 at 1:00 PM</td>
</tr>
<tr>
<td>Name of Organization:</td>
<td>The State of Nevada, Department of Health and Human Services, Division of Health Care Financing and Policy (DHCFP), Drug Use Review Board (DUR).</td>
</tr>
</tbody>
</table>

Note: *If at any time during the meeting an individual who has been named on the agenda or has an item specifically regarding them included on the agenda is unable to participate because of technical or other difficulties, please email tbenitez@dhcfp.nv.gov or call (775) 684-3730 and note at what time the difficulty started so that matters pertaining specifically to their participation may be continued to a future agenda if needed or otherwise addressed.*

**Webinar Registration:**

- [https://optum.webex.com/optum/onstage/g.php?MTID=e0a7030f0e87a1bc1f03d3eb085e0a6ec](https://optum.webex.com/optum/onstage/g.php?MTID=e0a7030f0e87a1bc1f03d3eb085e0a6ec)

Or go to [www.webex.com](http://www.webex.com) and enter the Event Number listed below.

Once you have registered for the meeting, you will receive an email message confirming your registration. This message will provide the information that you need to join the meeting.

**Event Number:**

- 641 557 826

Click “Join Now”
Follow the instructions that appear on your screen to join the audio portion of the meeting. Audio will be transmitted over the internet.

A password should not be necessary, but if asked use: Medicaid1!

For Audio Only:

Phone: 1-763-957-6300
Event: 641 557 826

[Please place your phone on mute unless providing public comment.]

**AGENDA**

1. **Call to Order and Roll Call**

2. **Public Comment on Any Matter on the Agenda** *(Owing to the lack of a physical location for this meeting, public comment is encouraged to be submitted in advance so that it may be included in meeting materials and given attention. No action may be taken upon a matter raised through public comment unless the matter itself has been specifically included on an agenda as an action item. Please provide your name in any comment for record keeping purposes. You may submit comments in writing via e-mail to tbenitez@dhcfp.nv.gov. There may be opportunity to take public comment via telephone, but phone participants should disconnect their call and re-join if they must take another call. Do not place your phone on hold or you may disrupt the meeting for other participants. This guidance applies for all periods of public comment referenced further in the agenda, such as those related to clinical presentations.)*

3. **Administrative**

   a. **For Possible Action**: Review and Approve Meeting Minutes from January 23, 2020.

   b. Status Update by the DHCFP.

4. **Clinical Presentations**

   a. **For Possible Action**: Discussion and possible adoption of updated prior authorization criteria and/or quantity limits for calcitonin gene-related peptide (CGRP) receptor inhibitors.

      1. Public comment on proposed clinical prior authorization criteria.
      2. Presentation of utilization and clinical information.
      3. Discussion by Board and review of utilization data.
      4. Proposed adoption of updated prior authorization criteria.

   b. **For Possible Action**: Discussion and possible adoption of updated prior authorization criteria and/or quantity limits for cystic fibrosis agents.

      1. Public comment on proposed clinical prior authorization criteria.
      2. Presentation of utilization and clinical information.

Nevada Department of Health and Human Services
Helping People -- It's Who We Are And What We Do
3. Discussion by Board and review of utilization data.
4. Proposed adoption of updated prior authorization criteria.

c. **For Possible Action:** Discussion and possible adoption of updated prior authorization criteria and/or quantity limits for narcolepsy agents.
   1. Public comment on proposed clinical prior authorization criteria.
   2. Presentation of utilization and clinical information.
   3. Discussion by Board and review of utilization data.
   4. Proposed adoption of updated prior authorization criteria.

d. **For Possible Action:** Discussion and possible adoption of prior authorization criteria and/or quantity limits for sickle cell anemia agents.
   1. Public comment on proposed clinical prior authorization criteria.
   2. Presentation of utilization and clinical information.
   3. Discussion by Board and review of utilization data.
   4. Proposed adoption of updated prior authorization criteria.

e. **For Possible Action:** Discussion and possible adoption of updated prior authorization criteria and/or quantity limits for proton pump inhibitors.
   1. Public comment on proposed clinical prior authorization criteria.
   2. Presentation of utilization and clinical information.
   3. Discussion by Board and review of utilization data.
   4. Proposed adoption of updated prior authorization criteria.

f. **For Possible Action:** Discussion and possible adoption of updated prior authorization criteria and/or quantity limits for tobacco cessation products.
   1. Public comment on proposed clinical prior authorization criteria.
   2. Presentation of utilization and clinical information.
   3. Discussion by Board and review of utilization data.
   4. Proposed adoption of updated prior authorization criteria.

g. **For Possible Action:** Discussion and possible adoption of updated prior authorization criteria and/or quantity limits for Toradol® (ketorolac tromethamine) tablets.
   1. Public comment on proposed clinical prior authorization criteria.
   2. Presentation of utilization and clinical information.
   3. Discussion by Board and review of utilization data.
   4. Proposed adoption of updated prior authorization criteria.

5. **Public Comment on any DUR Board Requested Report**

6. **DUR Board Requested Reports**
   
a. Opioid utilization – top prescribers and members.
      1. Discussion by the Board and review of utilization data.
2. **For Possible Action:** Requests for further evaluation or proposed clinical criteria to be presented at a later date.

b. Methadone utilization and place of service.
   1. Discussion by the Board and review of utilization data.
   2. **For Possible Action:** Requests for further evaluation or proposed clinical criteria to be presented at a later date.

c. Antibiotic utilization.
   1. Discussion by the Board and review of utilization data.
   2. **For Possible Action:** Requests for further evaluation or proposed clinical criteria to be presented at a later date.

7. **Public Comment on any Standard DUR Report**

8. **Standard DUR Reports**
   a. Review of Prescribing/Program Trends.
      1. Top 10 Therapeutic Classes for Q3 2019 and Q4 2019 (by Payment and by Claims).
   
   b. Concurrent Drug Utilization Review (ProDUR).
      2. Review of Top Encounters by Problem Type.
   
   c. Retrospective Drug Utilization Review (RetroDUR).
      1. Status of previous quarter.
      2. Status of current quarter.

9. **Closing Discussion**
   a. Public comments on any subject. (*Owing to the lack of a physical location for this meeting, public comment is encouraged to be submitted in advance so that it may be included in meeting materials and given attention. No action may be taken upon a matter raised through public comment unless the matter itself has been specifically included on an agenda as an action item. Please provide your name in any comment for record keeping purposes. You may submit comments in writing via e-mail to tbenitez@dhcfp.nv.gov. There may be opportunity to take public comment via telephone, but phone participants should disconnect their call and re-join if they must take another call. Do not place your phone on hold or you may disrupt the meeting for other participants. Public comments may be related to topics on the agenda or matters related to other topics per NRS 241.020(3)(3)(III).*)
   
   b. Date and location of the next meeting.
1. Discussion of the time of the next meeting.

c. Adjournment.

PLEASE NOTE: Items may be taken out of order at the discretion of the chairperson. Items may be combined for consideration by the public body. Items may be pulled or removed from the agenda at any time. If an action item is not completed within the time frame that has been allotted, that action item will be continued at a future time designated and announced at this meeting by the chairperson. All public comment may be limited to three minutes and written comments are encouraged if possible.

This notice and agenda have been posted online at http://dhcfp.nv.gov and http://notice.nv.gov as well as Carson City, Las Vegas, and Reno central offices for the Division of Health Care Financing and Policy. E-mail notice has been made to such individuals as have requested notice of meetings (to request notifications please contact tbenitez@dhcfp.nv.gov, or at 1100 East William Street, Suite 101, Carson City, Nevada 89701 or call Tanya Benitez at (775) 684-3730). At this time, in deference to Emergency Directive 006 dated March 22, 2020 and related directives which have discouraged certain in-person activities, notice has not been posted at other physical locations.

If you require a physical copy of supporting material for the public meeting, please contact tbenitez@dhcfp.nv.gov, or at 1100 East William Street, Suite 101, Carson City, Nevada 89701 or call Tanya Benitez at (775) 684-3730). Supporting material will also be posted online as referenced above.

All persons that have requested in writing to receive the Public Hearings agenda have been duly notified by mail or e-mail.

Note: We are pleased to make reasonable accommodations for members of the public with a disability and wish to participate. If accommodated arrangements are necessary, notify the Division of Health Care Financing and Policy as soon as possible and at least ten days in advance of the meeting, by e-mail at tbenitez@dhcfp.nv.gov in writing, at 1100 East William Street, Suite 101, Carson City, Nevada 89701 or call Tanya Benitez at (775) 684-3730.

Per Nevada Governor Sisolak’s Declaration of Emergency Directive 006; Subsection 3: The requirements contained in NRS 241.020 (4) (a) that public notice agendas be posted at physical locations within the State of Nevada are suspended.

Per Nevada Governor Sisolak’s Declaration of Emergency Directive 006; Subsection 4: Public bodies must still comply with requirements in NRS 241.020 (4)(b) and NRS 241.020 (4)(c) that public notice agendas be posted to Nevada’s notice website and the public body’s website, if it maintains one along with providing a copy to any person who has requested one via U.S. mail or electronic mail.

Per Nevada Governor Sisolak’s Declaration of Emergency Directive 006; Subsection 5: The requirement contained in NRS 241.020 (3)(c) that physical locations be available for the public to receive supporting material for public meetings is suspended.

Per Nevada Governor Sisolak’s Declaration of Emergency Directive 006; Subsection 6: If a public body holds a meeting and does not provide a physical location where supporting material is available to the public, the public body must provide on its public notice agenda the name and contact information for
the person designated by the public body from whom a member of the public may request supporting material electronically and must post supporting material to the public body’s website, if it maintains one.